Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) Will Announce Earnings of -$1.62 Per Share

Wall Street brokerages expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post earnings per share (EPS) of ($1.62) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.69) and the highest is ($1.53). Agios Pharmaceuticals reported earnings per share of ($1.78) during the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The company is expected to report its next quarterly earnings report on Tuesday, August 14th.

On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.41) per share for the current financial year, with EPS estimates ranging from ($6.73) to ($5.95). For the next year, analysts expect that the firm will post earnings of ($6.06) per share, with EPS estimates ranging from ($6.30) to ($5.77). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $11.93 million. During the same quarter in the prior year, the company earned ($1.56) earnings per share. The business’s revenue was down 16.2% compared to the same quarter last year.

AGIO has been the subject of several recent analyst reports. Piper Jaffray Companies reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. SunTrust Banks set a $115.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Citigroup initiated coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price objective for the company. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. Finally, Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 17th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $95.55.

Agios Pharmaceuticals stock traded up $1.28 during mid-day trading on Friday, hitting $84.94. 331,060 shares of the company were exchanged, compared to its average volume of 323,130. Agios Pharmaceuticals has a 1-year low of $51.62 and a 1-year high of $99.82. The firm has a market capitalization of $4.82 billion, a P/E ratio of -12.58 and a beta of 2.01.

In other news, insider Christopher Bowden sold 2,000 shares of the stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total transaction of $170,200.00. Following the sale, the insider now owns 2,881 shares in the company, valued at $245,173.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of the stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $85.95, for a total value of $176,197.50. Following the sale, the insider now owns 2,050 shares in the company, valued at approximately $176,197.50. The disclosure for this sale can be found here. Insiders have sold 159,277 shares of company stock worth $14,357,650 in the last 90 days. Company insiders own 3.02% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Xact Kapitalforvaltning AB bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $259,000. S&CO Inc. bought a new position in Agios Pharmaceuticals in the first quarter valued at about $278,000. M&T Bank Corp bought a new position in Agios Pharmaceuticals in the first quarter valued at about $293,000. HBK Investments L P bought a new position in Agios Pharmaceuticals in the fourth quarter valued at about $306,000. Finally, Aperio Group LLC bought a new position in Agios Pharmaceuticals in the first quarter valued at about $311,000. Institutional investors own 94.51% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply